Document:

Exhibit 10.12

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

SECOND
AMENDMENT TO THE EXCLUSIVE LICENSE AGREEMENT

 

This
Second Amendment to the Exclusive License Agreement (“Second Amendment”) effective as of August 3, 2021 (“Second Amendment
Effective Date”) is by and between: EISAI
INC.,
with its principal office at 100 Tice Blvd., Woodcliff Lake, NJ 07093, United States of America (“Eisai”) and ALLARITY
THERAPEUTICS
A/S,
with its principal office at Venlighedsvej 1, DK-2970 Hoersholm, Denmark (“Allarity”) (formerly known as Oncology Venture
ApS), with reference to the following:

 

WITNESSETH:

 

WHEREAS,
as of July 6, 2017, the Parties entered into an Exclusive License Agreement, (the “Original Agreement”) relating to the cancer
drug E7449 (now Stenoparib (2X-121)), a PARP inhibitor,

 

WHEREAS,
as of December 11, 2020, the Parties executed a First Amendment to said Exclusive License Agreement, expanding the Field;

 

WHEREAS,
Eisai and Allarity now desire to amend certain provisions of the Original Agreement, in order to (1) postpone the due date of the Extension
Payment (as defined below) by extending the deadline for Allarity’s Successful Completion of its first Phase 2 clinical trial for
Stenoparib; and (2) amend terms related to Eisai’s right of termination of Development.

 

NOW,
THEREFORE, in consideration of the foregoing premises, and the mutual promises and covenants of Parties set forth herein, the Parties
have agreed as follows:

 

	1.	Definitions

 

Capitalized
terms used in this Second Amendment and not defined herein shall have the meanings assigned thereto in the Original Agreement.

 

	2.	Amendments
                                            and Agreements

 

		1)	Section
                                            7.6 of the Original Agreement, “Extension Payment”, is hereby amended and restated
                                            in its entirety as follows:

 

Section
7.6 Extension Payment. If Allarity and/or its Affiliates or sublicensees have not achieved Successful Completion of the first Phase
2 Clinical Trial of the Product prior to December 31, 2022, then, in Allarity’s sole discretion, it may notify Eisai of its intention
to continue Development activities of the Compound. In the event that Eisai and Allarity mutually agree to such continued Development
activities by Allarity, Allarity shall pay a one-time payment to Eisai of [***] U.S. Dollars (the “Extension Payment”) within
thirty (30) days following December 31, 2022. Notwithstanding the foregoing, in the event that Allarity has not enrolled and dosed at
least thirty (30) patients with the first dose of cancer drug E7449 in the ongoing Phase 2 Ovarian Cancer Clinical Trial by July 1, 2022
then the Extension Payment shall become due and payable in full by July 30, 2022.

 

     

     

    

 

		2)	Section
                                            14.2(f)(i) of the Original Agreement, “Eisai Right of Termination for Development”,
                                            is hereby amended and restated in its entirety as follows:

 

Section
14.2(f) Eisai Right of Termination for Development.

 

		(i)	If
                                            Allarity and/or its Affiliates or sublicensees have not achieved Successful Completion of
                                            the first Phase 2 Clinical Trial of the Product prior to December 31, 2022 and Allarity elected
                                            not to pay the Extension Payment pursuant to Section 7.6, Eisai may terminate this Agreement
                                            in its entirety, in its sole discretion, at any time following thirty (30) days from December
                                            31, 2022, on at least one hundred and twenty (120) days prior written notice.

 

	3.	Effect

 

This
Second Amendment shall be effective from the Second Amendment Effective Date.

 

	4.	No
                                            Other Amendments

 

This
Second Amendment shall be deemed to be part of and incorporated into the Original Agreement. Except as expressly set forth in this Second
Amendment, all of the terms and conditions of the Original Agreement shall remain unchanged and are ratified, confirmed in all respects,
and remain in full force and effect.

 

	5.	Counterparts

 

This
Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. An executed signature page of this Second Amendment delivered by facsimile
transmission or by electronic mail in “portable document format” shall be as effective as an original executed signature
page.

 

[Signature
Page Follows]

 

     2

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Second Amendment through their duly authorized representatives and made effective
as of the Second Amendment Effective Date.

 

	Allarity Therapeutics A/S	 	Eisai, Inc.
	 	 	 
	By:	/s/
    James G. Cullem, J.D. 	 	By:	/s/
    Takashi Owa 
	Name: 	James G. Cullem, J.D. 	 	Name: 	Takashi Owa 
	Title:	Senior V.P., Corporate Development	 	Title:	Chief Medicine Creation Officer

Oncology Business Group

    Eisai Inc.
	 	 	 	 	 
	Date:	20 August 2021 	 	Date:	2021年8月23日

 

[Signature
Page to Second Amendment to Exclusive License Agreement between Allarity and Eisai]
 

 

3Exhibit
10.13

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

THIRD
AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

 

This
Third Amendment (“Third Amendment”) to Exclusive License Agreement effective as of September 28, 2021 (“Third Amendment
Effective Date”) is by and between: SMERUD MEDICAL RESEARCH INTERNATIONAL AS, a company organized and existing under the laws
of Norway, with a principal place of business is located at Thunes vei 2, N-0274 Oslo, Norway (“Smerud”) and ALLARITY THERAPEUTICS
A/S, a company organized and existing under the laws of Denmark, with a principal place of business at Venlighedsvej 1, DK-2970 Hoersholm,
Denmark (“Allarity”)(formerly Oncology Venture A/S), with reference to the following:

 

WITNESSETH:

 

WHEREAS,
as of June 25, 2020, the Parties entered into an Exclusive License Agreement, (the “Original Agreement”) relating to the cancer
drugs LiPlaCis® and 2X-l l l,

 

WHERAS,
as of December 17, 2021, the Parties executed a First Amendment to the Original Agreement extending the time period in which Smerud may
raise investment funding to support the licensed drug programs to April 1, 2021,

 

WHERAS,
as of March 12, 2021, the Parties executed a Second Amendment to the Original Agreement extending the time period in which Smerud may
raise investment funding to support the licensed drug programs to October 1, 2021

 

WHEREAS,
Smerud and Allarity now desire to amend certain provisions of the Original Agreement, in order to further extend the time period for
raising investment funding for the drug programs, to reflect the modifications, amendments, deletions and supplements set forth below.

 

NOW,
THEREFORE, in consideration of the foregoing premises, and the mutual promises and covenants of Parties set forth herein, the Parties
have agreed as follows:

 

		1.	Definitions

 

Capitalized
terms used in this First Amendment and not defined herein shall have the meanings assigned thereto in the Original Agreement.

 

		2.	Amendments
                                            and Agreements

 

		1)	In
Section 2.4 of the Original Agreement, “Financing” (as modified by the First Amendment to said Agreement) is hereby amended
and restated in its entirety as follows:

 

Financing.
No later than December 31, 2021, SMERUD or NewCo will raise no less than [***] in financing to support and advance the Clinical Development
Plans for both Licensed Drugs or at least [***] (the “Minimum Funding”) to support and advance the Clinical Development
Plan for only one selected Licensed Drug. SMERUD or NewCo will confirm the achievement of raising these funds by providing OV with financial
statements within thirty (30) days following any such financing. The funding may comprise a mix of investment capital, grant funding
and Third Party partnership funding. The Minimum Funding shall be used exclusively to Develop, Manufacture and Commercialize the Licensed
Drugs and shall not be used towards any other SMERUD drug development programs. The Minimum Funding is in addition to the value of the
in-kind CRO services that SMERUD will contribute in advancing the Licensed Drugs and conducting the Clinical Development Plan.

 

		3.	Effect

 

This
Third Amendment shall be effective from the Third Amendment Effective Date.

 

		4.	No
                                            Other Amendments

 

This
Third Amendment shall be deemed to be part of and incorporated into the Original Agreement. Except as expressly set forth in this Third
Amendment (together with the First Amendment), all of the terms and conditions of the Original Agreement shall remain unchanged and are
ratified, confirmed in all respects, and remain in full force and effect.

 

		5.	Counterparts

 

This
Third Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together
shall be deemed to constitute one and the same instrument. An executed signature page of this First Amendment delivered by facsimile
transmission or by electronic mail in “portable document format” shall be as effective as an original executed signature page.

 

[Signature
Page Follows]

     

     

    

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Third Amendment through their duly authorized representatives and made effective
as of the Third Amendment Effective Date.

 

	Allarity
    Therapeutics A/S	 	Smerud
    Medical Research International, AS
	 	 	 	 	 
	By:	/s/
James G. Cullem, J.D.	 	By:	/s/
Knut Smerud
	Name:	James
    G. Cullem, J.D.	 	Name:	Knut
    Smerud
	Title:
	Senior
                                            V.P., Corporate Development
	 	Title:
	Chief
                                            Executive Officer

	 	 	 	 	 
	Date:	September
    28, 2021	 	Date:	September
    29, 2021

 

{Signature
Page to Third Amendment to Exclusive License Agreement between OVand Smerud]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]